Connect with us

Health

Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial – GlobeNewswire

NEW YORK and MAINZ, GERMANY, Sept. 12, 2020 (GLOBE NEWSWIRE) —   NEW YORK and MAINZ, GERMANY, September 12 — Pfizer Inc. (NYSE: PFE) and BioNTech…

Published

on

NEW YORK and MAINZ, GERMANY, Sept. 12, 2020 (GLOBE NEWSWIRE) —
NEW YORKand MAINZ, GERMANY, September 12 Pfizer Inc.
(NYSE: PFE) and BioNTech SE
(NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
Enrollment in the trial has been proceeding as planned an…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending